Open an account

Cryo-Cell International

CCEL · NYSE American

$4.75+$0.10 (+2.15%)TodayMarket closed ·
Prev close $4.65

About CCEL

Cryo-Cell International, Inc. is a cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. The company is headquartered in Oldsmar, Florida and currently employs 72 full-time employees. The firm operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The firm stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The firm markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

Employees
72
Headquarters
Oldsmar, Florida
Listed
Apr 4, 1994
Sector
Health Care
Industry
Health Care Providers & Services
Website
cryo-cell.com

CCEL key statistics

Market cap
38.30M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
13.77K
Volume
6.88K
Open price
$4.65
High today
$4.85
Low today
$4.50
52 Week high
$4.90
52 Week low
$2.72

Cryo-Cell International (CCEL) at a glance

Cryo-Cell International (CCEL) last traded at $4.75, with a market cap of 38.30M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.50 and $4.85. The current price is 5.6% above the day's low and 2.1% below its high.

Volume so far is 6.88K shares, below the average of 13.77K shares a day.

Over the past year Cryo-Cell International has ranged from $2.72 to $4.90, and now sits 93% of the way up that range.

Cryo-Cell International met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q3 FY26 it reported $0.16 per share against an estimate of $0.0306.

CCEL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 168.4% on average.

  1. Q4 FY24: reported -$0.22 per share against an estimate of $0.0102
  2. Q1 FY25: reported $0.03 per share against an estimate of $0.00
  3. Q2 FY25: reported $0.04 per share against an estimate of -$0.051
  4. Q3 FY25: reported $0.09 per share against an estimate of -$0.051
  5. Q4 FY25: reported -$0.47 per share against an estimate of -$0.0918
  6. Q1 FY26: reported $0.01 per share against an estimate of -$0.0306
  7. Q2 FY26: reported $0.07 per share against an estimate of $0.00
  8. Q3 FY26: reported $0.16 per share against an estimate of $0.0306

CCEL news

  • Press releaseBusiness Wire

    Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Press releaseBusiness Wire

    Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American

  • Press releaseBusiness Wire

    Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks

  • Press releaseBusiness Wire

    Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Cryo-Cell Receives NYSE American Continued Listing Notice

  • Press releaseBusiness Wire

    Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

Similar companies

Companies in the same industry as Cryo-Cell International

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.